View Financial HealthRevium Rx 배당 및 자사주 매입배당 기준 점검 0/6Revium Rx 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.003%자사주 매입 수익률총 주주 수익률-0.003%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.공시 • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0공시 • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.공시 • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RVRC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RVRC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Revium Rx 배당 수익률 vs 시장RVRC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RVRC)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.0%분석가 예측 (RVRC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RVRC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RVRC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RVRC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RVRC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 05:53종가2026/03/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Revium Rx.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.
공시 • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0
공시 • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.
공시 • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.